Aktuellt
SENASTE
Redeye adjusts its estimates for the return of NASH to Sprint Bioscience. While the company could find a more proactive partner for NASH in the coming 12 months, we judge that the recent returns of PETRA01 and NASH expose underlying weaknesses in Sprint Bioscience’s business model. Further, the recently announced outcome of TO5 exercise aligned with our expectations. We lower our valuation.
LÄS MER
